Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis

Purpose Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis is a morbid endeavor. Despite improvement in perioperative management of these patients, there are subsets of patients requiring hospital readmission after discharge. We sought to identi...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2016-06, Vol.23 (6), p.1941-1947
Main Authors: Martin, Alexander S., Abbott, Daniel E., Hanseman, Dennis, Sussman, Jonathan E., Kenkel, Alexander, Greiwe, Parker, Saeed, Noor, Ahmad, Samar H., Sussman, Jeffrey J., Ahmad, Syed A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Chemotherapy, Cancer, Regional Perfusion - adverse effects
Combined Modality Therapy
Cytoreduction Surgical Procedures - adverse effects
Female
Follow-Up Studies
Gastrointestinal Oncology
Humans
Hyperthermia, Induced - adverse effects
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasms - pathology
Neoplasms - therapy
Oncology
Patient Readmission - statistics & numerical data
Peritoneal Neoplasms - secondary
Peritoneal Neoplasms - therapy
Postoperative Complications
Prognosis
Retrospective Studies
Risk Factors
Surgery
Surgical Oncology
Survival Rate
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis is a morbid endeavor. Despite improvement in perioperative management of these patients, there are subsets of patients requiring hospital readmission after discharge. We sought to identify variables associated with readmission rates for CRS/HIPEC. Methods We conducted a retrospective review of CRS/HIPEC cases at the University of Cincinnati between 1999 and 2014. Patient-, tumor-, and treatment-specific characteristics were evaluated. The association between patient- and outcome-specific variables for 30- and 90-day readmission were evaluated. Results Of 215 CRS/HIPEC patients, the 7-, 30-, and 90-day readmission rates were 9.8 % ( n  = 21), 14.9 % ( n  = 32), and 21.4 % ( n  = 46), respectively. The most common reasons for readmission within 90 days included abdominal pain ( n  = 14), intra-abdominal abscess ( n  = 9), malnutrition/failure to thrive ( n  = 8), and bowel obstruction ( n  = 7). The primary factor associated with readmission at all time points (7, 30, and 90 days) was the presence of an enterocutaneous fistula ( p  
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-016-5109-3